http://www.tucc.com Clinical advancements in the field of urology are featured in the news media every day. This RSS feed provides patients and physicians with the most up-to-date information on recent urologic advancements around the world. Mon, 20 May 2013 01:19:53 GMT http://www.tucc.com/FDA-Approves-New-Drug-Xofigo-to-Treat-Prostate-Cancer.29.519.html A new drug 'Xofigo' has been approved by the U.S. Food and Drug Administration to treat men with symptomatic late-stage (metastatic) castration-resistant prostate cancer that has attacked the bones but not other organs. Bayer and Algeta's drug  'Xofigo' (radium Ra 223 dichloride) is meant for men in who the cancer has spread after undergoing medical and surgical therapy to lower testosterone levels. Thu, 16 May 2013 07:00:00 GMT http://www.tucc.com http://www.tucc.com/Bone-targeted-therapies-evolve-in-prostate-cancer.29.518.html The treatment of bone metastases in prostate cancer has changed over the years, and several options are now either available or under development. Daniel P. Petrylak, MD, director of the Genitourinary Oncology Program at Yale Cancer Center in New Haven, Connecticut, spoke about advances in bone-targeted therapy at the 6th Annual Interdisciplinary Prostate Cancer Congress, which was held in New York City on March 16. “Bisphosphonates used to be the only option,” he said, “but treatment has evolved over the years.” Bone resorption and bone formation are dysregulated in prostate cancer, and clinical evidence indicates that both processes contribute to bone metastases. The mechanisms for bone metastases are complex, and include tumor stimulation of osteoclasts and osteoblasts, and the response of the bone microenvironment. In addition, factors independent of the tumor may contribute to bone resorption. Mon, 13 May 2013 07:00:00 GMT http://www.tucc.com http://www.tucc.com/New-test-improves-assessment-of-prostate-cancer-risk-study-says.29.517.html A new test can help distinguish aggressive prostate cancer from less threatening ones, potentially saving many men from unneeded operations for tumors that would never hurt them, researchers are reporting. The test, developed by Genomic Health, could triple the number of men who could confidently monitor their tumors rather than undergo surgery or radiation treatments, according to the company and to researchers. Fri, 10 May 2013 07:00:00 GMT http://www.tucc.com http://www.tucc.com/AUA-Many-men-with-erectile-dysfunction-untreated.29.516.html Only about a quarter of men diagnosed with erectile dysfunction (ED) receive treatment, despite the availability and heavy media promotion of treatments, according to a study presented at the annual meeting of the American Urological Association. Thu, 09 May 2013 07:00:00 GMT http://www.tucc.com http://www.tucc.com/Clinical-Evaluation-of-Treatment-with-Peyronies-Disease-with-Collagenase-Clostridium-Histolyticum.30.515.html TUCC physicians and clinical investigators Lawrence Karsh, M.D., and Jesse Mills, M.D., presented the results of a national clinical evaluation of the treatment of Peyronie’s Disease at the American Urological Association 2013 Annual Meeting. Three phase 3 studies have been conducted to examine the safety and efficacy of collagenase clostridium histolyticum (CCH) in subjects with Peyronie’s disease (PD). The effect of CCH on change in penile curvature deformity from baseline to end of study was analyzed by the subjects’ duration of disease or degree of plaque calcification. Treatment with CCH resulted in improvements in curvature deformity regardless of duration of disease or level of plaque calcification; although small differences were noted within the subgroups, they are not expected to be clinically meaningful. Tue, 07 May 2013 07:00:00 GMT http://www.tucc.com http://www.tucc.com/BPH-Drug-Prescribing-Increasing-in-the-US.29.514.html Physicians in the U.S. increasingly have been prescribing pharmacotherapy to treat lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (BPH), according to data from two studies presented at the American Urological Association annual meeting. Sun, 05 May 2013 07:00:00 GMT http://www.tucc.com http://www.tucc.com/Personal-Epigenetic-Signatures-Found-Consistent-in-Prostate-Cancer-Patients-Metastases.29.513.html In a genome-wide analysis of 13 metastatic prostate cancers, scientists at the Johns Hopkins Kimmel Cancer Center found consistent epigenetic “signatures” across all metastatic tumors in each patient. The discovery of the stable, epigenetic “marks” that sit on the nuclear DNA of cancer cells and alter gene expression, defies a prevailing belief that the marks vary so much within each individual’s widespread cancers that they have little or no value as targets for therapy or as biomarkers for treatment response and predicting disease severity. Tue, 30 Apr 2013 07:00:00 GMT http://www.tucc.com http://www.tucc.com/Data-support-robot-assisted-partial-nephrectomy-for-kidney-cancer.29.512.html Robot-assisted partial nephrectomy (RPN) is associated with intermediate-term oncologic and renal function outcomes equivalent to those of laparoscopic and open partial nephrectomy, according to a new study. Jihad H. Kaouk, MD, and colleagues at Cleveland Clinic's Glickman Urological and Kidney Institute reviewed outcomes of 134 patients who underwent RPN and who had a minimum of two years of follow-up. Of these, 70 had at least three to six years of follow-up. The cohort had a mean age of 59 years and a mean body mass index of 29.8 kg/m2. The mean tumor size based on computed tomography scans was 3 cm. Sun, 28 Apr 2013 07:00:00 GMT http://www.tucc.com http://www.tucc.com/Prostate-cancer-Call-to-test-men-in-their-40s-.29.511.html Men should be offered a screening test for prostate cancer in their late 40s, researchers say. The idea is controversial as prostate specific antigen (PSA) testing can be unreliable, throwing up false positive results that can cause undue worry and even treatment over something benign. But the Swedish team say checking every man aged 45-49 would predict nearly half of all prostate cancer deaths. Wed, 17 Apr 2013 07:00:00 GMT http://www.tucc.com http://www.tucc.com/Prostatic-Artery-Embolization-Safe-Effective-for-BPH-Symptoms.29.510.html Early findings from the first prospective U.S. trial of prostatic artery embolization (PAE) suggest this approach may be safe and effective for treating lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (BPH), researchers reported at the Society of Interventional Radiology's 38th Annual Scientific Meeting. Tue, 16 Apr 2013 07:00:00 GMT http://www.tucc.com http://www.tucc.com/Family-turns-loss-into-action---the-importance-of-prostate-cancer-screening.30.508.html When Bill Meyn lost his fight against prostate cancer three years ago he left behind a wonderful family. The Meyn family wants all men out there to know that getting a PSA test at the 9 Health Fair takes only a matter of minutes and can prevent a lifetime of heartbreak and loss for your family. According to Dr. Mark Jones, urologist with The Urology Center of Colorado, the best thing men can do for their health is be screened for prostate cancer. If prostate cancer is detected at an early stage, it is survivable and treatable. Dr. Jones has performed hundreds of robotic prostatectomies to treat prostate cancer. In this story, 9News examines the advancements in robotic surgery and the importance of annual prostate cancer screenings. Wed, 10 Apr 2013 07:00:00 GMT http://www.tucc.com http://www.tucc.com/Phase-III-Randomized-Placebo-Controlled-Study-of-Docetaxel-in-Combination-With-Zibotentan-in-Patients-With-Metastatic-Castration-Resistant-Prostate-Cancer.29.507.html As part of the ENTHUSE (Endothelin A Use) program, the efficacy and safety of zibotentan (ZD4054), an oral specific endothelin A receptor antagonist, has been investigated in combination with docetaxel in patients with metastatic castration-resistant prostate cancer (CRPC). Mon, 08 Apr 2013 07:00:00 GMT http://www.tucc.com http://www.tucc.com/Validation-of-a-Cell-Cycle-Progression-Gene-Panel-to-Improve-Risk-Stratification-in-a-Contemporary-Prostatectomy-Cohort.29.506.html Purpose We aimed to validate a previously described genetic risk score, denoted the cell-cycle progression (CCP) score, in predicting contemporary radical prostatectomy (RP) outcomes. Sun, 31 Mar 2013 07:00:00 GMT http://www.tucc.com http://www.tucc.com/Study-links-early-baldness-to-prostate-cancer-in-African-Americans.29.505.html New research finds a link between early baldness and cancer of the male reproductive gland known as the prostate. The study involved African-American men, a group at particularly high risk of prostate cancer. At first glance, there doesn’t seem to be an obvious connection between prostate cancer and baldness. But University of Pennsylvania researcher Charnita M. Zeigler-Johnson, PhD, says the two may be linked through a testosterone product called dihydrotestosterone, or DHT.  The hormonal chemical, Zeigler-Johnson explains, “is a form of testosterone that seems to be associated with male-pattern baldness and also connected to prostate cancer occurrence and prostate cancer progression.” Thu, 28 Mar 2013 07:00:00 GMT http://www.tucc.com http://www.tucc.com/First-in-Man-Evaluation-of-2-High-Affinity-PSMA-Avid-Small-Molecules-for-Imaging-Prostate-Cancer.29.504.html  This phase 1 study was performed to determine the pharmacokinetics and ability to visualize prostate cancer in bone, soft-tissue, and the prostate gland using I-MIP-1072 and I-MIP-1095, novel radiolabeled small molecules targeting prostate-specific membrane antigen.  Thu, 21 Mar 2013 07:00:00 GMT http://www.tucc.com